RNA's Quality Score rose 2 points on Wed, Oct 7, to -2. Its volume went quiet (3 chart checks started).
−3Long-term trend below its 200-day since February, down 83% in a year, and down over two years 4 more reasons behind RNA's -2, for Pro members.
Follow RNA's trial news. Pro members can get an alert when Atrium Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 39% in 3 months, 29% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 18% over the same 3 months.
Expected to report Mon Nov 9, after the close
After its last 2 reports it closed +1.9% on average, higher 1 of 2 times.
For Pro members
From Atrium Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
$264M in cash
No shelf registration of its own or at-the-market program on file in the last three years.
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
One per group is shown here.
RNA is #172 of 308 by Quality Score. The top three are shown with their scores, and more by name.
Expected to report Mon Nov 9, after the close (in 32 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 13, 2026After close | After close | -1.0% | +4.1% | +9.3% |
| May 14, 2026After close | After close | +1.6% | -0.3% | -1.7% |
Officers and directors with a Form 4 here in the last 12 months. Open one for their trades at every company.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders, and profits come straight from the SEC. That means Form 4 filings, 13F filings, and XBRL financial data on EDGAR. Where a company's SEC figures leave the Quality Score's sales, share count, or cash flow line empty, the score reads that figure from Massive's statements, and the Score tab says so. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch, and Yahoo Finance publish, shown as the headline, the source, and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.